Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2022 | 2019 | 2018 | 2017 | 2016 | 2015
Number of items: 11.

2022

Brown, Jennifer R., Eichhorst, Barbara, Hillmen, Peter, Lamanna, Nicole, O'Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Kazmierczak, Maciej, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda L., Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Salmi, Tommi, Wang, Megan (Der Yu), Fu, Lina, Li, Jessica, Wu, Kenneth, Cohen, Aileen and Shadman, Mazyar (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140. S. 19 - 24. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

2019

Younes, Anas, Sehn, Laurie H., Johnson, Peter ORCID: 0000-0003-2306-4974, Zinzani, Pier Luigi, Hong, Xiaonan, Zhu, Jun, Patti, Caterina, Belada, David ORCID: 0000-0002-4981-6188, Samoilova, Olga, Suh, Cheolwon, Leppae, Sirpa, Rai, Shinya, Turgut, Mehmet, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Cheung, Matthew C., Gurion, Ronit, Yeh, Su-Peng, Lopez-Hernandez, Andres, Duehrsen, Ulrich, Thieblemont, Catherine, Chiattone, Carlos Sergio, Balasubramanian, Sriram, Carey, Jodi, Liu, Grace, Shreeve, S. Martin, Sun, Steven, Zhuang, Sen Hong, Vermeulen, Jessica, Staudt, Louis M., Wilson, Wyndham, Fisher, Richard I., Engert, Andreas, Stadtmauer, Edward A. and Wei, Lee-Jen (2019). Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. J. Clin. Oncol., 37 (15). S. 1285 - 1307. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2018

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Hillmen, Peter, Seymour, John F., Coutre, Steven, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Schuh, Anna, Assouline, Sarit, Wendtner, Clemens-Martin, Roberts, Andrew W., Davids, Matthew S., Bloehdorn, Johannes, Munir, Talha, Boettcher, Sebastian, Zhou, Lang, Salem, Ahmed Hamed, Desai, Monali, Chyla, Brenda, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Gordon, Gary, Hallek, Michael and Wierda, William G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol., 36 (19). S. 1973 - 1984. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Walewski, Jan ORCID: 0000-0003-4247-2674, Hellmann, Andrzej, Siritanaratkul, Noppadol, Ozsan, Guner Hayri, Ozcan, Muhit, Chuncharunee, Suporn, Goh, Ai Sim, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Koren, Jan, Paszkiewicz-Kozik, Ewa, Wang, Bingxia, Singh, Shalini, Huebner, Dirk, Engert, Andreas and von Tresckow, Bastian (2018). Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy. Br. J. Haematol., 183 (3). S. 400 - 411. HOBOKEN: WILEY. ISSN 1365-2141

2017

Chyla, Brenda, Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Puvvada, Soham, Wendtner, Clemens, Davids, Matthew S., Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Wierda, William and Hallek, Michael (2017). Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial. Leuk. Lymphoma, 58. S. 234 - 236. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Wierda, William, Chyla, Brenda, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Wendtner, Clemens-Martin, Davids, Matthew, Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Stilgenbauer, Stephan and Hallek, Michael (2017). Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial. Clin. Lymphoma Myeloma Leuk., 17. S. S303 - 1. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

2016

Furman, Richard R., Hallek, Michael, Sharman, Jeffrey P., Hillmen, Peter, Zelenetz, Andrew D., Flinn, Ian W., Jurczak, Wojciech, Munugalavadla, Veerendra, Xiao, Yuanyuan, Zheng, Lianqing, Rao, Arati V., Dreiling, Lyndah K., Salles, Gilles A. and O'Brien, Susan M. (2016). Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Sehn, Laurie H., Hallek, Michael, Jurczak, Wojciech, Brown, Jennifer R., Barr, Paul M., Catalano, John, Coutre, Steven E., Furman, Richard R., Lamanna, Nicole, Loic, Ysebaert, Zelenetz, Andrew D., Sharman, Jeffrey P., Devos, Sven, Adewoye, Adeboye Henry, Kim, Yeonhee, Flinn, Ian W. and Salles, Gilles A. (2016). A Retrospective Analysis of Pneumocystis Jirovecii Pneumonia Infection in Patients Receiving Idelalisib in Clinical Trials. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Desai, Monali, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod, Gordon, Gary, Hallek, Michael and Wierda, William G. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol., 17 (6). S. 768 - 779. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Wendtner, Clemens-Martin, Byrd, John C., Eichhorst, Barbara, Foa, Robin, Hallek, Michael, Hillmen, Peter, Jager, Ulrich, Jurczak, Wojciech, Kelemen, Peter, Laribi, Kamel, Munir, Talha, Staber, Philipp B., Stilgenbauer, Stephan and Woyach, Jennifer Ann (2016). A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE). J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2015

Stilgenbauer, Stephan, Eichhorst, Barbara F., Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech, Mulligan, Stephen, Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod A., Gordon, Gary, Hallek, Michael and Wierda, William (2015). Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Fri Mar 29 15:14:21 2024 CET.